This Virta Health company profile covers the company's valuation, revenue, funding rounds, investors and history. Virta Health works in healthcare, with a focus on virtual metabolic care. It was founded in 2014 and is headquartered in Denver, Colorado, United States. Its latest valuation on record is US$2 billion (April 2021). Every figure links to a public source, and anything the company hasn't disclosed is marked as such.
Revenue
| Metric | Value | As of | Source |
|---|---|---|---|
| Total funding | About US$366 million to US$373 million in venture funding (as reported) | April 2021 | Fierce Healthcare |
Funding history
| Date | Round | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Apr 2021 | Series E | US$133M | US$2B | Tiger Global (lead) and others | Fierce Biotech |
| Dec 2020 | Series D | US$65M | About US$1.1B | See source | Built In Colorado |
Virta Health timeline
Key dates from the sources on this page, oldest first. Metric snapshots are listed after the funding events.
- 2014 — Virta Health is founded in Denver by Sami Inkinen (CEO) and co-founders.
- Dec 2020 — Series D: US$65M, valuing the company at About US$1.1B.
- Apr 2021 — Series E: US$133M, valuing the company at US$2B. Investors: Tiger Global (lead) and others.
- April 2021 — Total funding: About US$366 million to US$373 million in venture funding (as reported).
Investors
Overview
Virta Health provides virtual treatment for type 2 diabetes and obesity that aims to reverse diabetes, meaning lowering blood sugar to healthy levels while reducing or eliminating diabetes medications. Its approach centres on carefully supervised nutrition, typically a low-carbohydrate diet, combined with remote monitoring and support from physicians and health coaches through an app. Employers and health plans offer Virta to members, often paying only when patients achieve results. Virta was valued at US$2 billion in April 2021 after raising US$133 million in a Series E led by Tiger Global.
Sami Inkinen, the CEO, co-founded Virta in 2014. Inkinen previously co-founded Trulia, the real estate website acquired by Zillow, and is a competitive endurance athlete who became interested in metabolic health after being diagnosed with prediabetes despite his fitness. He worked with researchers specialising in nutritional ketosis to build a medically supervised treatment programme that could be delivered at scale.
Products and services
- Type 2 diabetes reversal: a medically supervised programme focused on nutrition, with medication adjustments by Virta physicians.
- Remote monitoring: connected devices to track blood sugar, weight and other measures.
- Coaching: health coaches who support behaviour change through the app.
- Obesity and weight management: programmes that can incorporate GLP-1 medications alongside nutrition support.
- Prediabetes programmes: support for people at risk of developing type 2 diabetes.
Funding
Virta raised early funding from investors including Venrock, Caffeinated Capital, Allegis Capital and Obvious Ventures. In December 2020 it raised a US$65 million Series D that valued it at about US$1.1 billion. In April 2021 it raised US$133 million in a Series E led by Tiger Global, doubling its valuation to US$2 billion, and said it had raised about US$366 million to US$373 million in total. We haven't found a newer priced round, so the 2021 valuation should be treated as historical.
Business model
Virta contracts with employers, health plans and government programmes, often with pricing tied to outcomes: payers pay more when patients reduce blood sugar and medications. This model aligns Virta's incentives with clinical results and lowers the risk for payers. Savings from reduced diabetes medications and complications are a key part of its value proposition.
Competition
Virta competes with digital diabetes and cardiometabolic programmes such as Omada Health and Teladoc's Livongo; with obesity care providers offering GLP-1 drugs, such as Ro and Hims & Hers; and with traditional care from primary care doctors and endocrinologists. GLP-1 medications such as semaglutide and tirzepatide have transformed the obesity and diabetes market, creating both competition and opportunities for programmes that support patients using them.
Virta Health at a glance
Virta Health is a Denver-based virtual metabolic care company co-founded in 2014 by Trulia co-founder Sami Inkinen. It treats type 2 diabetes and obesity through medically supervised nutrition, remote monitoring and coaching, paid by employers and health plans. It raised US$133 million at a US$2 billion valuation in April 2021, led by Tiger Global.
Timeline
- 2014: founded.
- 2017–2018: publishes clinical trial results showing improvements in blood sugar and medication use.
- December 2020: raises US$65 million and becomes a unicorn.
- April 2021: raises US$133 million at US$2 billion.
- 2023–2026: adds obesity programmes and GLP-1 support.
Clinical evidence
Virta has emphasised peer-reviewed research. A clinical study reported by the company found that most participants with type 2 diabetes reduced or eliminated insulin use after one year, along with improvements in blood sugar. Evidence matters because employers and insurers increasingly demand proof that digital health programmes deliver results. Long-term adherence to dietary changes remains a challenge for any nutrition-based treatment.
The GLP-1 era
New GLP-1 medications have produced substantial weight loss and blood sugar improvements, and demand has surged. They are expensive, however, and many patients stop taking them because of cost or side effects, often regaining weight. Programmes like Virta's position themselves as complementary: helping patients use medications appropriately, supporting nutrition and lifestyle changes, and potentially helping some patients reduce or stop medications. Payers facing high GLP-1 costs are interested in approaches that manage spending while maintaining results.
Who funds Virta Health
Virta's investors include Tiger Global, which led its Series E, along with Venrock, Caffeinated Capital, Allegis Capital and Obvious Ventures.
Who uses Virta Health
Virta's customers are employers, health plans and government programmes, and its patients are adults with type 2 diabetes, prediabetes or obesity.
Valuation context
Virta's 2021 valuation was set during the digital health boom. Our guide to health tech unicorns compares it with peers.
Risks
- GLP-1 competition: medications may change how payers address diabetes and obesity.
- Adherence: sustaining dietary changes is difficult for many patients.
- Payer budgets: employers scrutinise digital health spending.
- Stale valuation: the last priced round is from 2021.
Questions for employers
- How is pricing tied to outcomes?
- What results have similar employers seen?
- How does the programme work alongside GLP-1 coverage?
How the Virta programme works
A patient with type 2 diabetes enrols through their employer or health plan and receives a connected glucose meter, scale and access to the app. A Virta physician reviews their medications and creates a plan, and a health coach helps them adopt a low-carbohydrate eating pattern adapted to their preferences. Patients log blood sugar, weight and meals, and the care team adjusts medications as blood sugar improves, which is critical because some diabetes drugs can cause dangerously low blood sugar when diets change. Over months, many patients reduce medications and improve their health markers. Ongoing coaching aims to help them sustain changes over time.
Employers evaluating Virta can ask for outcome data from similar populations.
Latest developments (October 2026)
Chief executive Sami Inkinen told Axios in September 2025 that Virta would be ready to go public in 2026. We have not seen a filing as of October 2026. An industry review by Healthcare.Digital put its annualised revenue above US$160 million in late 2025, growing more than 80%, helped by demand for diabetes and obesity care that does not rely solely on GLP-1 drugs. See our health tech unicorns guide.
What to watch
Watch new funding, GLP-1 partnerships, clinical publications and payer contracts.
Takeaways
Patients may reduce diabetes medications with supervised nutrition. Founders can see how outcome-based pricing builds trust with payers. Investors should treat its valuation as a 2021 mark.
Sources
Every figure on this page comes from the public sources below. Where sources disagreed, we used the company's own announcement or a primary news report. Private-company data changes; check the date beside each figure.
Frequently asked questions
What does Virta Health do?
Virta Health is a healthcare / virtual metabolic care company headquartered in Denver, Colorado, United States. It was founded in 2014.
What is Virta Health's valuation?
Virta Health was valued at US$2 billion as of April 2021, according to Virta Health (company press release). Private company valuations are set at funding rounds or share sales and can change significantly between them.
How much revenue does Virta Health make?
Virta Health is a private company and has not publicly disclosed its revenue. Figures on third-party sites are usually modelled estimates rather than numbers reported by the company.
What was Virta Health's latest funding round?
The most recent financing we have verified is a series e in Apr 2021: US$133M, at a valuation of US$2B. Source: Fierce Biotech.
Who are Virta Health's investors?
Investors named in public announcements include Tiger Global, Caffeinated Capital, Venrock, Allegis Capital and Obvious Ventures.
Who founded Virta Health?
Virta Health was founded in 2014 by Sami Inkinen (CEO) and co-founders.
Is Virta Health a public company?
No. Virta Health is a private company (private, venture backed), so its shares are not traded on a stock exchange and it isn't required to publish its financial results.
Where is Virta Health headquartered?
Virta Health is headquartered in Denver, Colorado, United States.